GeneDx Holdings Corp. (WGS)

Market Cap	2.63B
Revenue (ttm)	305.45M
Net Income (ttm)	-52.29M
Shares Out	27.47M
EPS (ttm)	-1.94
PE Ratio	n/a
Forward PE	100.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,086,733
Open	102.68
Previous Close	101.58
Day's Range	90.26 - 103.56
52-Week Range	7.16 - 115.60
Beta	2.08
Analysts	Strong Buy
Price Target	82.60 (-13.81%)
Earnings Date	Feb 18, 2025

About WGS

GeneDx Holdings Corp., a genomics company, provides personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company accelerate the use of genomics and leverage clinical data to enable precision medicine as the standard of care. It utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patient...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Employees: 1,000
• Stock Exchange: NASDAQ
• Ticker Symbol: WGS
• Website: https://www.genedx.com

Financial Performance

In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $82.6, which is a decrease of -13.81% from the latest price.

Price Target

$82.6

(-13.81% downside)

Analyst Consensus: Strong Buy